Welcome to our dedicated page for ARROWHEAD PHARMACEUTICALS SEC filings (Ticker: ARWR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ARROWHEAD PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ARROWHEAD PHARMACEUTICALS's regulatory disclosures and financial reporting.
Arrowhead Pharmaceuticals director Matthew Gregory Cohen has filed an initial Form 3 indicating no current ownership of the company’s Common Stock. The filing lists a holding entry in Common Stock with total shares following the report shown as 0. This is a baseline disclosure of his position as a newly reported insider, rather than a buy or sell transaction.
Arrowhead Pharmaceuticals, Inc. announced that its Board of Directors appointed Dr. Matt Cohen, M.D., M.B.A., as a director, effective June 12, 2026. Dr. Cohen brings more than 25 years of healthcare investing and portfolio management experience, including senior roles at JP Morgan Asset Management and Vida Ventures.
He will receive standard non-employee director compensation plus a sign-on grant of restricted stock units valued at $887,000, scheduled to vest over three years. The company states there are no family relationships or appointment-related arrangements with other persons, and Dr. Cohen will enter into Arrowhead’s standard indemnity agreement.
ARWR submitted an amended Form 144/A reporting a proposed resale of 100,000 common shares by Daniel Apel. The filing lists the shares as issued for compensation (a bonus) with an original grant date of 04/15/2025 and the Form 144/A date of 04/22/2026.
ARWR insider notice: Hongbo Lu filed a Form 144/A disclosing proposed sale of 2,970 shares of common stock, with an aggregate amount shown as $228,298.95. The filing lists 03/15/2026 and an execution/filing date of 05/12/2026, and identifies the sale reason as compensation.
James Hamilton reported proposed sales of Common Stock via a Form 144/A. The filing lists a proposed sale of 10,000 shares. The filing also records past transactions: a sale of 10,000 shares on 03/05/2026 for $641,870.05, and multiple compensation issuances on 01/04/2026 totaling 10,000 shares across four line items (5,708; 542; 1,628; 2,122).
Arrowhead Pharmaceuticals director Hongbo Lu reported an open-market sale of company stock. On the reported date, Lu sold 2,970 shares of Arrowhead Pharmaceuticals common stock at a price of $76.88 per share in a single transaction.
The filing states this sale was made under a pre-arranged Rule 10b5-1 trading plan, which is designed to allow insiders to sell shares on a scheduled basis. After this transaction, Lu directly owned 52,012 shares of Arrowhead Pharmaceuticals common stock, which includes shares underlying previously granted restricted stock units, some of which are still subject to vesting conditions.
Arrowhead Pharmaceuticals, Inc. reported a sharp swing to a loss for the quarter ended March 31, 2026. Revenue was $73.7 million, down from $542.7 million a year earlier, when it booked large milestone payments, leading to a net loss attributable to Arrowhead of $132.7 million versus net income of $370.4 million in the prior-year quarter.
For the first six months, revenue totaled $337.8 million and the net loss was $101.9 million. Cash, cash equivalents and restricted cash were $188.5 million, with available-for-sale securities of $1.60 billion, supporting ongoing R&D spending of $350.5 million over six months and a growing collaboration portfolio with Sarepta, Novartis and Sanofi.
Arrowhead Pharmaceuticals reported fiscal 2026 second quarter revenue of $73.7 million, down sharply from $542.7 million a year earlier, leading to a net loss of $132.7 million or -$0.93 per diluted share versus net income of $370.4 million or $2.75 previously. Total cash resources rose to $1.78 billion as of March 31, 2026, supported by concurrent offerings of $700 million in 0.00% convertible senior notes due 2032 and a $230 million common equity issuance, plus a capped call to limit dilution.
The company highlighted growing commercial traction for REDEMPLO in familial chylomicronemia syndrome, with more than 400 prescriptions, about 180 patients shipped, and most use in patients new to the APOC3 class. Arrowhead also expanded REDEMPLO’s global regulatory footprint, advanced its RNAi pipeline in cardiometabolic disease and obesity, and signed a worldwide license with Madrigal Pharmaceuticals for ARO-PNPLA3, including a $25 million upfront payment and up to $975 million in potential milestones.
Arrowhead Pharmaceuticals filed a Schedule 13G reporting that FMR LLC beneficially owned 7,349,106.75 shares of common stock, representing 5.2% of the class as shown in the filing. The cover shows sole voting power of 7,323,647.12 and sole dispositive power of 7,349,106.75. The filing lists an Exhibit referencing a related 13d-1(k)(1) agreement.